

Roberto Diaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11931019/publications.pdf>

Version: 2024-02-01

28
papers

838
citations

516710

16
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

1482
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Nanoparticles That Deliver a Sustained, Specific Release of Paclitaxel to Irradiated Tumors. <i>Cancer Research</i> , 2010, 70, 4550-4559.	0.9	136
2	Hypothyroidism as a Consequence of Intensity-Modulated Radiotherapy With Concurrent Taxane-Based Chemotherapy for Locally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 468-476.	0.8	87
3	Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer. <i>Molecular Carcinogenesis</i> , 2015, 54, 1147-1158.	2.7	78
4	Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1 α and STAT-3. <i>Angiogenesis</i> , 2013, 16, 903-917.	7.2	72
5	Noninvasive assessment of cancer response to therapy. <i>Nature Medicine</i> , 2008, 14, 343-349.	30.7	66
6	HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. <i>Oncotarget</i> , 2014, 5, 9980-9991.	1.8	52
7	Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 435-440.	0.6	45
8	The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. <i>Cancer Research</i> , 2002, 62, 4514-8.	0.9	44
9	Linear release nanoparticle devices for advanced targeted cancer therapies with increased efficacy. <i>Polymer Chemistry</i> , 2010, 1, 93.	3.9	28
10	Radiation-induced tumor neoantigens: imaging and therapeutic implications. <i>American Journal of Cancer Research</i> , 2011, 1, 390-412.	1.4	23
11	Complex effects of Ras proto-oncogenes in tumorigenesis. <i>Carcinogenesis</i> , 2003, 25, 535-539.	2.8	22
12	Intensity-Modulated Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer: Toxicities and Efficacy. <i>Oncologist</i> , 2012, 17, 673-681.	3.7	19
13	Is Proton Therapy a "Pro" for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database. <i>Frontiers in Oncology</i> , 2019, 8, 678.	2.8	19
14	Inhibition of Ras oncogenic activity by Ras protooncogenes. <i>International Journal of Cancer</i> , 2005, 113, 241-248.	5.1	18
15	Recombinant Peptides as Biomarkers for Tumor Response to Molecular Targeted Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 6421-6429.	7.0	17
16	Dosimetric and cost comparison of first fraction imaging versus fractional re-imaging on critical organ dose in vaginal cuff brachytherapy. <i>Practical Radiation Oncology</i> , 2013, 3, 256-262.	2.1	13
17	MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. <i>Clinical Breast Cancer</i> , 2022, 22, e214-e223.	2.4	10
18	Commentary on "Accelerated partial breast irradiation consensus statement: Update of an ASTRO Evidence-Based Consensus Statement". <i>Practical Radiation Oncology</i> , 2017, 7, e159-e163.	2.1	9

#	ARTICLE	IF	CITATIONS
19	Outcomes of selective whole breast irradiation following lumpectomy with intraoperative radiation therapy for hormone receptor positive breast cancer. <i>American Journal of Surgery</i> , 2019, 218, 749-754.	1.8	7
20	Frequency of whole breast radiation therapy after intraoperative radiation therapy due to criteria identified by lumpectomy. <i>Brachytherapy</i> , 2017, 16, 174-180.	0.5	6
21	Thyroid Storm After Intensity-Modulated Radiation Therapy: A Case Report and Discussion. <i>Oncologist</i> , 2009, 14, 233-239.	3.7	5
22	Quantitative Changes in Intratumoral Habitats on MRI Correlate With Pathologic Response in Early-stage ER/PR+ HER2 ⁺ Breast Cancer Treated With Preoperative Stereotactic Ablative Body Radiotherapy. <i>Journal of Breast Imaging</i> , 2022, 4, 273-284.	1.3	4
23	Determining glioma response to radiation therapy using recombinant peptides. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1787-1796.	2.4	3
24	The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes. <i>Journal of Geriatric Oncology</i> , 2021, 12, 219-226.	1.0	3
25	Antiangiogenic activity of the HSP90 inhibitor ganetespib in pancreatic cancer models. <i>FASEB Journal</i> , 2013, 27, lb572.	0.5	2
26	Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 320-335.	1.6	1
27	Factors predictive of aborted intraoperative breast radiation using the intrabeam system. <i>Journal of the American College of Surgeons</i> , 2015, 221, e51-e52.	0.5	1
28	Heat shock protein 90 (HSP90) inhibition in squamous cell carcinoma of the head and neck (SCCHN): An in vitro analysis with a focus on p16 status.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2552-2552.	1.6	0